{"id":1072938,"date":"2023-12-24T04:17:39","date_gmt":"2023-12-24T06:17:39","guid":{"rendered":"https:\/\/teknomers.com\/fr\/outlook-therapeutics-ce-sont-les-derniers-chiffres-trimestriels\/"},"modified":"2023-12-24T04:17:44","modified_gmt":"2023-12-24T06:17:44","slug":"outlook-therapeutics-ce-sont-les-derniers-chiffres-trimestriels","status":"publish","type":"post","link":"https:\/\/teknomers.com\/fr\/outlook-therapeutics-ce-sont-les-derniers-chiffres-trimestriels\/","title":{"rendered":"Outlook Therapeutics : Ce sont les derniers chiffres trimestriels"},"content":{"rendered":"


\n<\/p>\n

\n

Outlook Therapeutics a tenu sa conf\u00e9rence financi\u00e8re r\u00e9guli\u00e8re le 22 d\u00e9cembre 2023 et a publi\u00e9 les chiffres du dernier trimestre, clos le 30 septembre 2023.<\/p>\n

La perte par action a \u00e9t\u00e9 estim\u00e9e \u00e0 0,050 $. Au m\u00eame trimestre de l’ann\u00e9e derni\u00e8re, Outlook Therapeutics a d\u00e9clar\u00e9 un b\u00e9n\u00e9fice par action de -0,060 USD.<\/p>\n

La perte par action pour l’ensemble de l’exercice s’est \u00e9lev\u00e9e \u00e0 0,240 $. L’ann\u00e9e pr\u00e9c\u00e9dente, les livres avaient -0,310 USD par action.<\/p>\n

Equipe \u00e9ditoriale finanzen.net<\/p>\n<\/div>\n

\n

Produits \u00e0 effet de levier s\u00e9lectionn\u00e9s sur Outlook Therapeutics<\/h2>\n

Avec les knock-outs, les investisseurs sp\u00e9culatifs peuvent participer de mani\u00e8re disproportionn\u00e9e aux mouvements de prix. S\u00e9lectionnez simplement le levier que vous souhaitez et nous vous montrerons les produits ouverts appropri\u00e9s sur Outlook Therapeutics.<\/p>\n

L’effet de levier doit \u00eatre compris entre 2 et 20<\/p>\n

Publicit\u00e9<\/span><\/div>\n


\n
ttn-fr-28<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Outlook Therapeutics a tenu sa conf\u00e9rence financi\u00e8re r\u00e9guli\u00e8re le 22 d\u00e9cembre 2023 et a publi\u00e9 les chiffres du dernier trimestre, clos le 30 septembre 2023. La perte par action a \u00e9t\u00e9 estim\u00e9e \u00e0 0,050 $. Au m\u00eame trimestre de l’ann\u00e9e derni\u00e8re, Outlook Therapeutics a d\u00e9clar\u00e9 un b\u00e9n\u00e9fice par action de -0,060 USD. La perte par […]<\/p>\n","protected":false},"author":1,"featured_media":986707,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[379,5296,65,70682,317,62719,9399],"class_list":["post-1072938","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance","tag-chiffres","tag-derniers","tag-les","tag-outlook","tag-sont","tag-therapeutics","tag-trimestriels"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/1072938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/comments?post=1072938"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/1072938\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media\/986707"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media?parent=1072938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/categories?post=1072938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/tags?post=1072938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}